|
|
Résultats pour
 brevets
1.
|
AUTOLOGOUS SOMATIC STEM CELL THERAPY, METHOD OF CONTROLLABLE PREPARATION OF THERAPEUTIC COMPOSITION AND PROCEDURE OF ADAPTIVE TREATMENT OF IVF PATIENT
| Numéro d'application |
19266550 |
| Statut |
En instance |
| Date de dépôt |
2025-07-11 |
| Date de la première publication |
2025-11-06 |
| Propriétaire |
CELL THERAPY HOLDINGS, LLC (USA)
|
| Inventeur(s) |
- Feskov, Alexander
- Zhylkova, Levgeniia
- Zhilkov, Stanislav
- Feskova, Irina
- Feskov, Vladislav
|
Abrégé
A blood product containing peripheral blood mononuclear cells (PBMCs) in an amount of at least 4 million cells per milliliter and human chorionic gonadotropin (HCG in an amount of at least 150 international units (IU) per milliliter. A method of preparing the blood product, including applying HCG to a female patient, then obtaining PBMCs from the female patient, then adding HCG to the obtained PBMCs. A method of culturing PBMCs, including applying HCG to a female patient, then culturing PBMCs obtained from the female patient at a time after the HCG was applied to the patient. A method of in vitro fertilization, including applying HCG to a female patient, culturing PBMCs obtained from the patient after the HCG was applied to the patient, introducing the cultured PBMCs into the uterus of the patient, and transferring at least one embryo into the uterus of the patient.
Classes IPC ?
- A61K 38/24 - Hormone folliculostimulante [FSH]Gonadotropines chorioniques, p. ex. HCGHormone lutéinisante [LH]Hormone thyréotrope [TSH]
- A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
- A61K 35/14 - SangSang artificiel
- A61K 40/10 - Immunothérapie cellulaire caractérisée par le type de cellules
- A61K 40/40 - Immunothérapie cellulaire caractérisée par les antigènes ciblés ou présentés par les cellules du système immunitaire
- C12N 5/078 - Cellules du sang ou du système immunitaire
- C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
|
2.
|
METHOD OF PRODUCING A PERIPHERAL BLOOD MONONUCLEAR CELL COMPOSITION SUITABLE FOR REPAIRING OR ENGINEERING A TISSUE
| Numéro d'application |
18604611 |
| Statut |
En instance |
| Date de dépôt |
2024-03-14 |
| Date de la première publication |
2024-08-15 |
| Propriétaire |
CELL THERAPY HOLDINGS, LLC (USA)
|
| Inventeur(s) |
- Feskov, Alexander
- Feskova, Irina
- Zhylkova, Ievgeniia
- Zhilkov, Stanislav
|
Abrégé
Disclosed is a method of in vitro fertilization wherein the embryo is implanted into the uterus of a female patient at least two, an preferably three to twelve months after the eggs are retrieved from the patient in order to reduce the effect of autoimmune rejection of the embryo by the patient's autoimmune system and increase the probability and success of pregnancy and wherein prior to embryo implantation, the endometrium in the uterus is prepared for embryo implantation by introducing peripheral blood mononuclear cells (PBMCs) into the uterus. The procedure is combined with cryopreservation techniques to preserve the oocytes or the IVF-produced embryos of the patient.
Classes IPC ?
- A61B 17/435 - Instruments ou procédés de gynécologie ou d'obstétrique pour la reproduction ou la fertilisation pour la transplantation d'embryons
- A61D 19/00 - Instruments ou procédés pour la reproduction ou la fertilisation
- A61D 19/04 - Instruments ou procédés pour la reproduction ou la fertilisation pour la transplantation d'embryons
- A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
- A61K 35/14 - SangSang artificiel
- C12N 5/078 - Cellules du sang ou du système immunitaire
|
3.
|
Method of producing a peripheral blood mononuclear cell composition suitable for repairing or engineering a tissue
| Numéro d'application |
17510653 |
| Numéro de brevet |
11957384 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2021-10-26 |
| Date de la première publication |
2022-02-10 |
| Date d'octroi |
2024-04-16 |
| Propriétaire |
CELL THERAPY HOLDINGS, LLC (USA)
|
| Inventeur(s) |
- Feskov, Alexander
- Feskova, Irina
- Zhylkova, Ievgeniia
- Zhilkov, Stanislav
|
Abrégé
A method of in vitro fertilization wherein the embryo is implanted into the uterus of a female patient at least two, and preferably three to twelve months after the eggs are retrieved from the patient in order to reduce the effect of autoimmune rejection of the embryo by the patient's autoimmune system and increase the probability and success of pregnancy and wherein prior to embryo implantation, the endometrium in the uterus is prepared for embryo implantation by introducing peripheral blood mononuclear cells (PBMCs) into the uterus. The procedure is combined with cryopreservation techniques to preserve the oocytes or the IVF-produced embryos of the patient.
Classes IPC ?
- A61B 17/435 - Instruments ou procédés de gynécologie ou d'obstétrique pour la reproduction ou la fertilisation pour la transplantation d'embryons
- A61D 19/00 - Instruments ou procédés pour la reproduction ou la fertilisation
- A61D 19/04 - Instruments ou procédés pour la reproduction ou la fertilisation pour la transplantation d'embryons
- A61K 35/14 - SangSang artificiel
- C12N 5/078 - Cellules du sang ou du système immunitaire
- A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
|
4.
|
Autologous somatic stem cell therapy, method of controllable preparation of therapeutic composition and procedure of adaptive treatment of IVF patient
| Numéro d'application |
17371436 |
| Numéro de brevet |
12377134 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2021-07-09 |
| Date de la première publication |
2021-10-28 |
| Date d'octroi |
2025-08-05 |
| Propriétaire |
CELL THERAPY HOLDINGS, LLC (USA)
|
| Inventeur(s) |
- Feskov, Alexander
- Zhylkova, Ievgeniia
- Zhilkov, Stanislav
- Feskova, Irina
- Feskov, Vladislav
|
Abrégé
A blood product containing peripheral blood mononuclear cells (PBMCs) in an amount of at least 4 million cells per milliliter and human chorionic gonadotropin (HCG in an amount of at least 150 international units (IU) per milliliter. A method of preparing the blood product, including applying HCG to a female patient, then obtaining PBMCs from the female patient, then adding HCG to the obtained PBMCs. A method of culturing PBMCs, including applying HCG to a female patient, then culturing PBMCs obtained from the female patient at a time after the HCG was applied to the patient. A method of in vitro fertilization, including applying HCG to a female patient, culturing PBMCs obtained from the patient after the HCG was applied to the patient, introducing the cultured PBMCs into the uterus of the patient, and transferring at least one embryo into the uterus of the patient.
Classes IPC ?
- A61K 38/24 - Hormone folliculostimulante [FSH]Gonadotropines chorioniques, p. ex. HCGHormone lutéinisante [LH]Hormone thyréotrope [TSH]
- A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
- A61K 35/14 - SangSang artificiel
- A61K 40/10 - Immunothérapie cellulaire caractérisée par le type de cellules
- A61K 40/40 - Immunothérapie cellulaire caractérisée par les antigènes ciblés ou présentés par les cellules du système immunitaire
- C12N 5/078 - Cellules du sang ou du système immunitaire
- C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
|
5.
|
Method of in vitro fertilization with delay of embryo transfer and use of peripheral blood mononuclear cells
| Numéro d'application |
16160436 |
| Numéro de brevet |
11185348 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2018-10-15 |
| Date de la première publication |
2019-04-18 |
| Date d'octroi |
2021-11-30 |
| Propriétaire |
CELL THERAPY HOLDINGS, LLC (USA)
|
| Inventeur(s) |
- Feskov, Alexander
- Feskova, Irina
- Zhylkova, Ievgeniia
- Zhilkov, Stanislav
|
Abrégé
A method of in vitro fertilization wherein the embryo is implanted into the uterus of a female patient at least two, and preferably three to twelve months after the eggs are retrieved from the patient in order to reduce the effect of autoimmune rejection of the embryo by the patient's autoimmune system and increase the probability and success of pregnancy and wherein prior to embryo implantation, the endometrium in the uterus is prepared for embryo implantation by introducing peripheral blood mononuclear cells (PBMCs) into the uterus. The procedure is combined with cryopreservation techniques to preserve the oocytes or the IVF-produced embryos of the patient.
Classes IPC ?
- A61B 17/435 - Instruments ou procédés de gynécologie ou d'obstétrique pour la reproduction ou la fertilisation pour la transplantation d'embryons
- A61D 19/04 - Instruments ou procédés pour la reproduction ou la fertilisation pour la transplantation d'embryons
- A61K 35/14 - SangSang artificiel
- C12N 5/078 - Cellules du sang ou du système immunitaire
- A61D 19/00 - Instruments ou procédés pour la reproduction ou la fertilisation
- A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
|
6.
|
Autologous somatic cell therapy, method of controllable preparation of therapeutic composition and procedure of adaptive treatment of IVF patient
| Numéro d'application |
15688385 |
| Numéro de brevet |
11091737 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2017-08-28 |
| Date de la première publication |
2018-03-01 |
| Date d'octroi |
2021-08-17 |
| Propriétaire |
CELL THERAPY HOLDINGS, LLC (USA)
|
| Inventeur(s) |
- Feskov, Alexander
- Zhylkova, Ievgeniia
- Zhilkov, Stanislav
- Feskova, Irina
- Feskov, Vladislav
|
Abrégé
A blood product containing peripheral blood mononuclear cells (PBMCs) in an amount of at least 4 million cells per milliliter and human chorionic gonadotropin (HCG in an amount of at least 150 international units (IU) per milliliter. A method of preparing the blood product, including applying HCG to a female patient, then obtaining PBMCs from the female patient, then adding HCG to the obtained PBMCs. A method of culturing PBMCs, including applying HCG to a female patient, then culturing PBMCs obtained from the female patient at a time after the HCG was applied to the patient. A method of in vitro fertilization, including applying HCG to a female patient, culturing PBMCs obtained from the patient after the HCG was applied to the patient, introducing the cultured PBMCs into the uterus of the patient, and transferring at least one embryo into the uterus of the patient.
Classes IPC ?
- C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
- C12N 5/078 - Cellules du sang ou du système immunitaire
- A61K 35/14 - SangSang artificiel
- A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
- A61K 38/24 - Hormone folliculostimulante [FSH]Gonadotropines chorioniques, p. ex. HCGHormone lutéinisante [LH]Hormone thyréotrope [TSH]
|
7.
|
Method of in vitro fertilization with delay of embryo transfer and use of peripheral blood mononuclear cells
| Numéro d'application |
13655257 |
| Numéro de brevet |
10271876 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2012-10-18 |
| Date de la première publication |
2013-07-04 |
| Date d'octroi |
2019-04-30 |
| Propriétaire |
CELL THERAPY HOLDINGS, LLC (USA)
|
| Inventeur(s) |
- Feskov, Alexander
- Feskova, Irina
- Zhylkova, Ievgeniia
- Zhilkov, Stanislav
|
Abrégé
A method of in vitro fertilization wherein the embryo is implanted into the uterus of a female patient at least two, and preferably three to twelve months after the eggs are retrieved from the patient in order to reduce the effect of autoimmune rejection of the embryo by the patient's autoimmune system and increase the probability and success of pregnancy and wherein prior to embryo implantation, the endometrium in the uterus is prepared for embryo implantation by introducing peripheral blood mononuclear cells (PBMCs) into the uterus. The procedure is combined with cryopreservation techniques to preserve the oocytes or the IVF-produced embryos of the patient.
Classes IPC ?
- A61B 17/435 - Instruments ou procédés de gynécologie ou d'obstétrique pour la reproduction ou la fertilisation pour la transplantation d'embryons
- A61D 19/00 - Instruments ou procédés pour la reproduction ou la fertilisation
- A61D 19/04 - Instruments ou procédés pour la reproduction ou la fertilisation pour la transplantation d'embryons
- A61K 35/14 - SangSang artificiel
- C12N 5/078 - Cellules du sang ou du système immunitaire
- A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
|
|